Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer
Yıl: 2019 Cilt: 20 Sayı: 1 Sayfa Aralığı: 8 - 12 Metin Dili: İngilizce DOI: 10.4274/imj.galenos.2018.91668 İndeks Tarihi: 14-04-2020
Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer
Öz: Introduction: To determine the clinical and pathologic factorsthat are risk factors for metastasis of the lymph nodes (pelvicand/or aortic lymph nodes) in cases who underwent stagingsurgery due to endometrial carcinoma.Methods: The clinical and pathological characteristics of 143patients who underwent staging surgery between 2007 and2016 were retrospectively analyzed. Linear regression analysis,logistic regression analysis, Spearman correlation and Receiveroperator curve tests were used to determine risk factors forlymph node metastasis. P<0.05 was considered significant inall statistical evaluations.Results: Thirteen cases (9.1%) had lymph node metastasis[5 cases (3.5%) only pelvic, 3 cases (2.1%) only paraaortic, 5cases (3.5%) both pelvic and paraaortic lymph node]. In linearregression analysis, there was a significant correlation betweenlymph node metastasis and non-endometrioid histologicaltype, deep myometrial invasion (≥50% invasion depth),advanced histologic grade, lymphovascular space invasion,positive peritoneal cytology and tumor size (p<0.05). Thecorrelation between tumor size and lymph node metastasiswas positive, and Receiver operator curve revealed 4.25 cmtumor size was the most appropriate cut-off value for risk oflymph node metastasis (sensitivity=83%, specificity=75%). Inlogistic regression analysis, lymphovascular space invasionwas the only independent risk factor for nodal metastasis (odssratio: 11.8; 95% confidence interval: 1.8-75.4, p=0.009).Conclusion: In endometrial cancer cases, lymphovascularspace invasion is the only independent risk factor for lymphnode metastasis. There is linear correlation between tumorsize and lymph node metastasis. Further studies is neededto determine the limit value of tumor size for lymph nodemetastasis.
Anahtar Kelime: Konular:
Endometriyum Kanserinde Lenf Nodu Metastazı için Risk Faktörlerinin Değerlendirilmesi
Öz: Amaç: Endometriyum kanseri nedeni ile evreleme operasyonu yapılan olgularda lenf nodu (pelvik ve/veya paraaortik lenf nodları) metastazı için risk oluşturan klinik ve patolojik faktörlerin belirlenmesidir. Yöntemler: Çalışmamızda 2007-2016 yılları arasında endometriyum kanseri tanısı ile evreleme cerrahisi uygulanan 143 olgunun klinik ve patolojik özellikleri retrospektif olarak incelendi. Lenf nodu metastazı için risk faktörlerinin belirlenmesinde doğrusal regresyon analizi, lojistik regresyon analizi, Spearman korelasyon testi ve işlem karakteristik eğrisi testleri kullanıldı. Tüm istatistiksel değerlendirmeler için p<0,05 anlamlı kabul edildi. Bulgular: Beş olguda (%3,5) sadece pelvik, 3 olguda (%2,1) sadece paraaortik, 5 olguda (%3,5) ise hem pelvik hem de paraaortik lenf nodu olmak üzere 13 olguda (%9,1) lenf nodu metastazı mevcuttu. Doğrusal regresyon analizinde non-endometrioid histolojik tip, derin miyometrial invazyon (≥%50 invazyon derinliği), ileri histolojik grade, lenfovasküler alan invazyonu, pozitif peritoneal sitoloji ve tümör boyutu ile lenf nodu metastazı arasında anlamlı ilişki bulundu (p<0,05). Tümör boyutu ile lenf nodu metastazı arasında pozitif korelasyon mevcuttu ve işlem karakteristik eğrisinde 4,25 cm tümör boyutu lenf nodu metastazı için en uygun sınır değer olarak tespit edildi (duyarlılık %83, özgüllük %75). Regresyon analizinde ise lenfovasküler alan invazyonu lenf nodu metastazı için bağımsız tek risk faktörü olarak belirlendi (odss oranı: 11,8; %95 güven aralığı: 1,8-75,4; p=0,009). Sonuç: Endometriyal kanserli olgularda lenfovasküler alan invazyonu lenf nodu metastazı için bağımsız tek risk faktörüdür. Tümör boyutu ile lenf nodu metastazı arasındaki korelasyon ise doğrusaldır. Lenf nodu metastazı için tümör boyutunun sınır değerini belirlemede yeni çalışmalara ihtiyaç vardır
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
- 2. T.C. Health Ministry, Turkish Public Health Agency. Turkey Cancer Statistics. [Internet]. Ankara, GA, Turkey: T.C. Sağlık Bakanlığı; 2017 [cited 2017 Oct 12]. Available from: http://kanser.gov.tr/Dosya/ca_istatistik/2014-RAPOR._ uzun.pdf
- 3. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505.
- 4. Shaw E, Farris N, McNeil J, Friedenreich C. Obesity and Endometrial cancer.
- Recent Results Cancer Res 2016; 208: 107-36. 5. Werner HM, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Amant F, et al. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol 2012; 125: 103-8.
- 6. Toptaş T, Şimşek T, Karaveli Ş. Prognostic risk factors for lymph node involvement in patients with endometrial cancer. Turk J Obstet Gynecol 2017; 14: 52-7.
- 7. Kang S, Nam JH, Bae DS, Kim JW, Kim MH, Chen X, et al. Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group Study. Cancer 2017; 123: 263-72.
- 8. Tas EE, Yavuz AF. The prognostic significance of preoperative serum cancer antigen 15-3 levels in endometrial carcinomas. Saud Med J 2017; 38: 1096- 100.
- 9. Haldorsen IS, Salvesen HB. What is the best preoperative imaging for endometrial cancer? Curr Oncol Rep 2016; 18: 25.
- 10. Tschernichovsky R, Diver EJ, Schorge JO, Goodman A. The role of lymphadenectomy versus sentinel lymph node biopsy in early-stage endometrial cancer: a review of the literature. Am J Clin Oncol 2016; 39: 516-21.
- 11. Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systemic review and meta-analysis. Am J Obstet Gynecol 2017; 216: 459-76.e10.
- 12. Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol 2015; 125: 1006-26.
- 13. Orr JW Jr, Taylor PT Jr. Surgical management of endometrial cancer: how much is enough? Gynecol Oncol 2008; 109: 1-3.
- 14. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60(8 Suppl): 2035-41.
- 15. Sari ME, Yalcin İ, Sahin H, Meyanli NM, Gungor T. Risk factors for paraaortic lymph node metastasis in endometrial cancer. Int J Clin Oncol 2017; 22: 937- 44.
- 16. Guntupalli SR, Zighelboim I, Kizer NT, Zhang Q, Powell MA, Thaker PH, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol 2012; 124: 31-5.
- 17. Orr JW Jr, Taylor PT Jr. Surgical management of endometrial cancer: how much is enough? Gynecol Oncol 2008; 109: 1-3.
- 18. Benedet JL, Bender H, Jones H, Ngan HY, Pecoreli S. FIGO staging classifications and cinica guidelines in the management of gynecological cancers. FIGO Committee on Gynecologic Oncology.Int J Gynaecol Obstet 200; 70: 209-62.
- 19. Thomas MB, Marianai A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systemic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol 2017; 107: 186-9.
- 20. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103-4.
- 21. Tejerizo-Garcia A, Jimenez-Lopez JS, Munoz-Gonzalez JL, Bartolome-Sotillos S, Margueta-Margues L, Lopez-Gonzalez G, et al. Overall survival and diseasefree survival in endometrial cancer:prognostic factors in 276 patients. Onco Targets Ther 2013; 9: 1305-13.
- 22. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the managemet of endometrial cancer. Cochrane Database Syst Rev 2017; 10: CD007585.
- 23. Stalberg K, Kjolhede P, Bjurberg M, Borgfeldt C, Dahm-Kahler P, Falconer H, et al. Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study-On behalf of the Swedish Gynecological Cancer Group. Int J Cancer 2017; 140: 2693-700.
- 24. Jorge S, Hou JY, Tergas AI, Burke WM, Huang Y, Hu JC, et al. Magnitude of risk for nodal metastasis associated with lymphovascular space invasion for endometrial cancer. Gynecol Oncol 2016; 140: 387-93.
- 25. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000; 182: 1506-19.
- 26. Vergas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, et al. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 2014; 133: 216-20.
- 27. Cox Bauer CM, Greer DM, Kram J JF, Kamelle SA. Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer. Gynecol Oncol 2016; 141: 199-205.
| APA | Tas E, YEĞİN G, Keskin H, KIR E, Yavuz A (2019). Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. , 8 - 12. 10.4274/imj.galenos.2018.91668 |
| Chicago | Tas Emre Erdem,YEĞİN Gülin Feykan,Keskin Huseyin Levent,KIR Edip Alptuğ,Yavuz Ayse Filiz Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. (2019): 8 - 12. 10.4274/imj.galenos.2018.91668 |
| MLA | Tas Emre Erdem,YEĞİN Gülin Feykan,Keskin Huseyin Levent,KIR Edip Alptuğ,Yavuz Ayse Filiz Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. , 2019, ss.8 - 12. 10.4274/imj.galenos.2018.91668 |
| AMA | Tas E,YEĞİN G,Keskin H,KIR E,Yavuz A Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. . 2019; 8 - 12. 10.4274/imj.galenos.2018.91668 |
| Vancouver | Tas E,YEĞİN G,Keskin H,KIR E,Yavuz A Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. . 2019; 8 - 12. 10.4274/imj.galenos.2018.91668 |
| IEEE | Tas E,YEĞİN G,Keskin H,KIR E,Yavuz A "Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer." , ss.8 - 12, 2019. 10.4274/imj.galenos.2018.91668 |
| ISNAD | Tas, Emre Erdem vd. "Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer". (2019), 8-12. https://doi.org/10.4274/imj.galenos.2018.91668 |
| APA | Tas E, YEĞİN G, Keskin H, KIR E, Yavuz A (2019). Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. İstanbul Medical Journal, 20(1), 8 - 12. 10.4274/imj.galenos.2018.91668 |
| Chicago | Tas Emre Erdem,YEĞİN Gülin Feykan,Keskin Huseyin Levent,KIR Edip Alptuğ,Yavuz Ayse Filiz Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. İstanbul Medical Journal 20, no.1 (2019): 8 - 12. 10.4274/imj.galenos.2018.91668 |
| MLA | Tas Emre Erdem,YEĞİN Gülin Feykan,Keskin Huseyin Levent,KIR Edip Alptuğ,Yavuz Ayse Filiz Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. İstanbul Medical Journal, vol.20, no.1, 2019, ss.8 - 12. 10.4274/imj.galenos.2018.91668 |
| AMA | Tas E,YEĞİN G,Keskin H,KIR E,Yavuz A Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. İstanbul Medical Journal. 2019; 20(1): 8 - 12. 10.4274/imj.galenos.2018.91668 |
| Vancouver | Tas E,YEĞİN G,Keskin H,KIR E,Yavuz A Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer. İstanbul Medical Journal. 2019; 20(1): 8 - 12. 10.4274/imj.galenos.2018.91668 |
| IEEE | Tas E,YEĞİN G,Keskin H,KIR E,Yavuz A "Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer." İstanbul Medical Journal, 20, ss.8 - 12, 2019. 10.4274/imj.galenos.2018.91668 |
| ISNAD | Tas, Emre Erdem vd. "Assessment of Risk Factors for Lymph Node Metastasis in Endometrial Cancer". İstanbul Medical Journal 20/1 (2019), 8-12. https://doi.org/10.4274/imj.galenos.2018.91668 |
